Yardstick Research tear-sheet / pharma & life sciences CRM cohort
Definitive Healthcare
Identity
- Founded: 2011 [VENDOR-CLAIMED - https://www.definitivehc.com/about]
- HQ: Framingham, Massachusetts (U.S. headquarters; additional offices in Sweden and India) [VENDOR-CLAIMED - https://www.definitivehc.com/about]
- Legal entity: Definitive Healthcare, LLC [VENDOR-CLAIMED - https://www.definitivehc.com/about]
- Funding: Publicly traded on NASDAQ (DH). Went public via NASDAQ IPO in 2021. Prior funding included PE backing from Insight Partners and other investors pre-IPO. [THIRD-PARTY - NASDAQ: DH public listing]
- Headcount: UNKNOWN. Not disclosed on current vendor pages. [UNKNOWN]
- Recent news (last 12 months):
- May 2026 - Definitive Healthcare data made available on Databricks Marketplace, enabling analytics customers to access DH data directly within the Databricks ecosystem. [VENDOR-CLAIMED - https://www.definitivehc.com/news]
- April 2026 - Launched Digital Audiences product, described as "a smarter way to reach healthcare consumers, providers, and more" for campaign targeting. [VENDOR-CLAIMED - https://www.definitivehc.com/news]
- Ongoing - 2024 Sustainability Report published; DefinitiveCares volunteer program operational. [VENDOR-CLAIMED - https://www.definitivehc.com/about]
- May 2025 - HMPS26 (Healthcare Marketing and Pharma Sales Conference) recap published, signaling active participation in pharma commercial marketing events. [VENDOR-CLAIMED - https://www.definitivehc.com/news]
- Archetype: Healthcare market intelligence and data platform. Definitive Healthcare provides structured, continuously updated data on healthcare organizations, physicians, payers, and clinical experts across the U.S. healthcare system. Core products - HospitalView, PhysicianView, Atlas (all-payor and prescription claims), Monocl ExpertInsight (KOL/scientific expert data), Populi Digital Audiences, and Carevoyance (sales enablement) - serve pharma commercial teams, medical device companies, healthcare IT vendors, and consulting firms. The platform is primarily a data and intelligence subscription rather than a workflow automation or field force CRM system.
Total score: 61.2 / 100
- Stage fit:
- Foundation (<40 readiness): no - Enterprise subscription model, no self-serve free tier, complex data platform. Not suitable for early-stage companies without active commercial intelligence or sales enablement needs.
- Pilot (40-59): conditional - Single-product pilots (e.g., PhysicianView for a brand launch territory build or Monocl for KOL mapping) are possible but pricing opacity limits entry point evaluation.
- Scale (60-79): yes - This is the primary fit zone. Publicly traded company with enterprise-grade data products and demonstrated deployments across pharma, medical device, and healthcare IT customers including Grifols USA, DePuy Synthes, and AdaptHealth.
- Optimization (80+): no - The platform is a data intelligence layer, not a full workflow automation system. For buyers seeking a CRM-integrated field force platform or next-best-action engine, Definitive Healthcare does not reach Optimization-stage fit in this cohort.
- One-line verdict: Established healthcare market intelligence data platform with strong provider and claims data assets - best as a data foundation layer for commercial teams, limited by moderate pharma-CRM specialization (3/4 vs. 4/4 for pure-play pharma CRM tools) and no public pricing.
Headline numbers
| Metric | Value | Evidence |
|---|---|---|
| Free tier? | No - enterprise sales only | [VENDOR-CLAIMED - https://www.definitivehc.com/] |
| Pricing | Not publicly disclosed | [UNKNOWN] |
| Hospital profiles | 9,000+ hospital and IDN profiles | [VENDOR-CLAIMED - https://www.definitivehc.com/] |
| Physician data | 3M+ physicians, nurses, and allied health professionals | [VENDOR-CLAIMED - https://www.definitivehc.com/] |
| Physician groups | 130,000+ physician group profiles | [VENDOR-CLAIMED - https://www.definitivehc.com/] |
| Claims data | Billions of medical and prescription claims; hundreds of millions of unique patients (de-identified) | [VENDOR-CLAIMED - https://www.definitivehc.com/] |
| KOL/expert data | 16M+ medical and scientific experts via Monocl ExpertInsight | [VENDOR-CLAIMED - https://www.definitivehc.com/] |
| Named customers | Grifols USA, DePuy Synthes, AdaptHealth, Cooper Surgical, Intera Oncology | [VENDOR-CLAIMED - https://www.definitivehc.com/about] |
| Public entity | NASDAQ: DH | [THIRD-PARTY - NASDAQ public listing] |
Dimension scores
| Dimension | Score | Weight | Weighted | Evidence |
|---|---|---|---|---|
| AI capability depth | 2/4 | 15 | 7.5 | [VENDOR-CLAIMED] Advanced analytics capabilities described for clinical trend analysis, market segmentation, and audience targeting. April 2026 Digital Audiences product launch signals AI-assisted targeting capability. Databricks Marketplace integration (May 2026) enables AI/ML workloads on DH data. Gaps: no specific AI model disclosure, no published accuracy benchmarks, no proprietary AI engine described. The platform is primarily a structured data product with analytics UI rather than a native AI inference layer. Analytics tooling is described as "advanced analytics" without AI-specific methodology disclosure. [VENDOR-CLAIMED - https://www.definitivehc.com/] |
| Workflow integration depth | 3/4 | 20 | 15.0 | [VENDOR-CLAIMED] Salesforce Health Cloud and Veeva Vault CRM integrations listed in D1 record. Databricks Marketplace integration (May 2026) demonstrates modern data ecosystem connectivity. Data Management and Integrations service described as enabling customers to "enrich your systems with our data." Carevoyance sales enablement platform is a workflow-adjacent surface. Gaps: specific CRM integration architecture, bidirectional sync scope, and field-level mapping are not publicly documented. [VENDOR-CLAIMED - https://www.definitivehc.com/, https://www.definitivehc.com/news] |
| Vertical specialization | 3/4 | 20 | 15.0 | [VENDOR-CLAIMED + THIRD-PARTY] Definitive Healthcare serves pharma/biotech but also medical device, healthcare IT, consulting, and health plans - it is not a pure-play pharma CRM or field force tool. The platform's data assets (hospital profiles, physician data, claims) are used across multiple healthcare-adjacent verticals, which limits the pharma-CRM-specific depth relative to purpose-built vendors. Biopharma is a named primary vertical with use cases for drug launches, KOL engagement, and provider targeting. Monocl ExpertInsight for scientific expert data is a pharma-specific differentiator. [VENDOR-CLAIMED - https://www.definitivehc.com/about, https://www.definitivehc.com/solutions] |
| Implementation + time-to-value | 3/4 | 5 | 3.75 | [VENDOR-CLAIMED] Data subscription model with existing products (HospitalView, PhysicianView, Atlas, Monocl) implies faster data access than custom-built platforms. Databricks Marketplace integration further accelerates data delivery for analytics-ready buyers. Carevoyance sales enablement platform has a UI-based workflow surface. Gaps: no published implementation timeline, no TTV guarantees. [VENDOR-CLAIMED - https://www.definitivehc.com/] |
| Data + compliance posture (HIPAA/21CFR11) | 3/4 | 20 | 15.0 | [VENDOR-CLAIMED - PARTIAL] Privacy page confirms HIPAA-compliant digital audiences for the consumer data product (225M+ de-identified consumers). Registered as a data broker in California, Vermont, Oregon, and Texas. GDPR compliance confirmed. Processes data "securely and compliantly" per vendor statements. Gaps: SOC 2 certification, ISO 27001, and 21 CFR Part 11 compliance are not surfaced on any public page. No published trust center or audit date found. HIPAA BAA availability is [UNKNOWN] for the core platform (confirmed only for the consumer data / Digital Audiences product). [VENDOR-CLAIMED - https://www.definitivehc.com/privacy] |
| Pricing + scalability | 3/4 | 5 | 3.75 | [UNKNOWN - PARTIAL] No public rate card, but Definitive Healthcare is a publicly traded company (NASDAQ: DH) with annual revenue and cost structure disclosed in SEC filings, providing more pricing-context transparency than fully private competitors. The pricing page exists at /pricing but pricing details were not accessible during research. Hard pricing-transparency penalty applied. Subscription-based model with product-level tiers is the standard DH commercial structure inferred from industry context. [UNKNOWN for specific pricing; THIRD-PARTY for public market positioning] |
| Vendor strength + named-customer evidence | 3/4 | 15 | 11.25 | [VENDOR-CLAIMED + THIRD-PARTY] Named customers include Grifols USA, DePuy Synthes, AdaptHealth, Cooper Surgical, and Intera Oncology. Publicly traded status (NASDAQ: DH) provides financial stability evidence. Long operational history since 2011. Databricks and Salesforce ecosystem partnerships signal tier-1 commercial infrastructure relationships. Gaps: no peer-reviewed outcome studies, no G2 or KLAS rating surfaced; named customers skew toward medical device and alternate site care rather than top-20 pharma brands. [VENDOR-CLAIMED - https://www.definitivehc.com/about; THIRD-PARTY - NASDAQ: DH] |
| Total | 100 | 71.25 − 10 (hard) = 61.25 ≈ 61.2 |
Pricing detail
Definitive Healthcare does not publish pricing on any public surface reviewed during research. A /pricing page exists on the vendor website but pricing details were not accessible.
Hard pricing-transparency penalty applied: no public pricing found. This is a hard penalty (−10 points), reducing the headline score from the pre-penalty total of 71.25 to 61.25 (displayed as 61.2). The hard penalty reflects complete pricing opacity with no market-facing signals at any band or range level.
As a publicly traded company (NASDAQ: DH), Definitive Healthcare's annual revenue is disclosed in SEC filings. The product structure (HospitalView, PhysicianView, Atlas, Monocl, Populi, Carevoyance) suggests modular subscription pricing with use-case-level licensing. Buyers should request a detailed pricing proposal by product and seat count.
Integrations
The following integrations are listed in Definitive Healthcare's D1 record and are relevant to the pharma-lifesci-crm cohort:
- Salesforce Health Cloud - Listed in D1 integrations. Definitive Healthcare's Data Management and Integrations service is designed to "enrich your systems with our data," supporting connectivity to CRM platforms. Specific Salesforce Health Cloud integration architecture is not publicly documented. [UNKNOWN depth - listed in D1 record]
- Veeva Vault CRM - Listed in D1 integrations. Specific Veeva Vault CRM integration architecture is not publicly documented. [UNKNOWN depth - listed in D1 record]
Additional ecosystem integration: Databricks Marketplace (May 2026) enables direct data access for analytics workloads. [VENDOR-CLAIMED - https://www.definitivehc.com/news]
Editorial assessment
Definitive Healthcare is the most horizontally positioned vendor in this cohort. Its core strength is the breadth and depth of its underlying data assets: 9,000+ hospital profiles, 3M+ healthcare professionals, billions of de-identified claims, and 16M+ KOL and scientific expert records via Monocl ExpertInsight. This data foundation makes DH a credible input into pharma commercial operations - territory design, KOL identification, prescriber targeting, and patient journey analysis - but the platform functions primarily as a data subscription layer, not a CRM or field force orchestration system.
The vertical-specialization score of 3/4 (rather than 4/4 as with pure-play pharma CRM vendors) reflects this horizontal positioning accurately. DH's customer base spans medical device (DePuy Synthes), alternate site care (AdaptHealth), and pharma, but its named customer evidence skews less toward top-20 branded pharma than competitors like Within3 or H1. The April 2026 Digital Audiences product and May 2026 Databricks Marketplace integration demonstrate product evolution toward activation and analytics-ecosystem connectivity, but neither moves the platform closer to the CRM-and-workflow core that this cohort prioritizes.
The hard pricing-transparency penalty is the largest single drag on the headline score. As a publicly traded company with SEC-disclosed revenue, DH's financial position is more transparent than private competitors, but per-product pricing remains entirely opaque to buyers entering a competitive evaluation. Combined with the absence of a publicly accessible trust center documenting HIPAA BAA availability, SOC 2 certification scope, and audit dates, procurement teams face more due-diligence friction than the platform's market position and financial stability would suggest.
The optimal use case for Definitive Healthcare in a pharma commercial stack is as a data foundation layer feeding into a CRM or field force system - not as a standalone CRM replacement. Buyers that pair DH's provider intelligence with a dedicated field force tool (Aktana, Salesforce Health Cloud native) will extract more value than those treating it as an all-in-one solution.
Best for
- Stage: Scale (60-79). Conditional for Optimization as a data foundation layer in a multi-tool commercial stack.
- Company profile: Mid-to-large pharmaceutical, biotech, or medical device company with active territory planning, KOL identification, prescriber targeting, or market access analytics needs. Buyers that already have a CRM deployment and need high-quality provider and claims data to enrich it.
- Industry fit: Pharma commercial (territory design, prescriber targeting, launch planning), medical affairs (KOL identification via Monocl ExpertInsight), clinical operations (site selection via claims data), medical device (hospital and IDN profiling). Less optimized for buyers seeking a field force CRM with workflow automation natively built in.
- Sales motion: Enterprise subscription procurement; likely owned by Commercial Insights, Medical Affairs, or Sales Operations. Multi-product deployment common at large pharma.
- Annual tooling budget: $50K-$500K+ estimated depending on product scope (no public data; inference from NASDAQ-listed enterprise SaaS positioning).
- Skip if: You need (a) a field force CRM or next-best-action engine rather than a data intelligence subscription, (b) published SOC 2 certification and HIPAA BAA documentation before procurement sign-off, (c) transparent pricing before budget approval, (d) named pharma case studies with verified script-lift or field-force outcomes, or (e) 21 CFR Part 11 electronic records compliance documentation for FDA submission contexts.
Right-of-reply
Definitive Healthcare received this tear-sheet seven calendar days before publication of the Yardstick Research 2026 Yardstick Report, including all measured numbers, sample outputs, and editorial assessment. Definitive Healthcare was given the opportunity to flag factual errors - incorrect pricing, misquoted feature availability, outdated screenshots, factual misstatement in the editorial assessment. Definitive Healthcare was not given the opportunity to request a score revision, dispute the rubric or its weights, withdraw from inclusion, negotiate ranking placement, or suggest changes to the editorial assessment beyond factual correction. Where a vendor flagged a factual correction, the correction was applied if verified and noted here; where a vendor disputed scoring, the dispute is recorded in the appendix but the score stands. Silence from the vendor during the right-of-reply window was treated as no objection.
Right-of-reply gaps
Specific [UNKNOWN] items surfaced in the dossier and explicitly raised with the vendor in right-of-reply:
- SOC 2 Type II status. Held or not held? Audit date and scope?
- ISO 27001 status. Held or not held?
- HIPAA BAA availability for core platform. The privacy page confirms HIPAA compliance for the Digital Audiences consumer data product. Is a BAA available for the core HospitalView / PhysicianView / Atlas platform? Scope?
- 21 CFR Part 11 support. Does the platform support 21 CFR Part 11 for FDA submission contexts?
- Veeva Vault CRM integration architecture. What is the specific data-flow, field-level mapping, and bidirectional sync scope?
- Salesforce Health Cloud integration architecture. Same question.
- Current headcount. Not disclosed on public pages; needed for vendor-viability assessment.
- Pricing model. Product-level subscription rates, seat counts, data volume tiers.
Sources
Definitive Healthcare first-party: - https://www.definitivehc.com/ - https://www.definitivehc.com/about - https://www.definitivehc.com/solutions - https://www.definitivehc.com/privacy - https://www.definitivehc.com/news
Third-party: - NASDAQ: DH (public company listing)
Products referenced: - HospitalView - https://www.definitivehc.com/ - PhysicianView - https://www.definitivehc.com/ - Atlas All-Payor and Prescription Claims - https://www.definitivehc.com/ - Monocl ExpertInsight - https://www.definitivehc.com/ - Populi Digital Audiences (launched April 2026) - https://www.definitivehc.com/news - Carevoyance sales enablement - https://www.definitivehc.com/ - Databricks Marketplace integration (May 2026) - https://www.definitivehc.com/news